← Back to headlines
Braveheart Raises Over $382 Million in IPO
Cardiac drug developer Braveheart successfully completed its Initial Public Offering, securing more than $382 million in funding.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
